SurModics (SRDX) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
SurModics Reports Third Quarter Fiscal 2015 Results
August 5, 2015 7:30 AM EDTGAAP Revenue Growth of 9% to $15.9 Million and GAAP EPS of $0.30 versus $0.26 Medical Device Business Revenue up 8%; IVD up 13% Continued Progress Developing Our Drug Coated Balloon Platform Raises Fiscal 2015 Revenue and EPS Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2015 third quarter, ended June 30, 2015.
According to SurModics President... More
